Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Freija E F Hogenhuis

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
British Journal of Clinical Pharmacology|January 28, 2021
No association between use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) studyRoos S G Sablerolles, Freija E F Hogenhuis, Melvin Lafeber, et al.
European Journal of Hospital Pharmacy : Science and Practice|June 27, 2020
COvid MEdicaTion (COMET) study: protocol for a cohort studyRoos S G Sablerolles, Freija E F Hogenhuis, Melvin Lafeber, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
British Journal of Clinical Pharmacology|January 28, 2021
No association between use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) studyRoos S G Sablerolles, Freija E F Hogenhuis, Melvin Lafeber, et al.
European Journal of Hospital Pharmacy : Science and Practice|June 27, 2020
COvid MEdicaTion (COMET) study: protocol for a cohort studyRoos S G Sablerolles, Freija E F Hogenhuis, Melvin Lafeber, et al.
Pageof 1